TY - JOUR
T1 - The use of Ebola convalescent plasma to treat Ebola virus disease in resource-constrained settings
T2 - a perspective from the field
AU - van Griensven, Johan
AU - De Weggheleire, Anja
AU - Delamou, Alexandre
AU - Smith, Peter G
AU - Edwards, Tansy
AU - Vandekerckhove, Philippe
AU - Bah, Elhadj Ibrahima
AU - Colebunders, Robert
AU - Herve, Isola
AU - Lazaygues, Catherine
AU - Haba, Nyankoye
AU - Lynen, Lutgarde
N1 - © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.
PY - 2016
Y1 - 2016
N2 - The clinical evaluation of convalescent plasma (CP) for the treatment of Ebola virus disease (EVD) in the current outbreak, predominantly affecting Guinea, Sierra Leone, and Liberia, was prioritized by the World Health Organization in September 2014. In each of these countries, nonrandomized comparative clinical trials were initiated. The Ebola-Tx trial in Conakry, Guinea, enrolled 102 patients by 7 July 2015; no severe adverse reactions were noted. The Ebola-CP trial in Sierra Leone and the EVD001 trial in Liberia have included few patients. Although no efficacy data are available yet, current field experience supports the safety, acceptability, and feasibility of CP as EVD treatment. Longer-term follow-up as well as data from nontrial settings and evidence on the scalability of the intervention are required. CP sourced from within the outbreak is the most readily available source of anti-EVD antibodies. Until the advent of effective antivirals or monoclonal antibodies, CP merits further evaluation.
AB - The clinical evaluation of convalescent plasma (CP) for the treatment of Ebola virus disease (EVD) in the current outbreak, predominantly affecting Guinea, Sierra Leone, and Liberia, was prioritized by the World Health Organization in September 2014. In each of these countries, nonrandomized comparative clinical trials were initiated. The Ebola-Tx trial in Conakry, Guinea, enrolled 102 patients by 7 July 2015; no severe adverse reactions were noted. The Ebola-CP trial in Sierra Leone and the EVD001 trial in Liberia have included few patients. Although no efficacy data are available yet, current field experience supports the safety, acceptability, and feasibility of CP as EVD treatment. Longer-term follow-up as well as data from nontrial settings and evidence on the scalability of the intervention are required. CP sourced from within the outbreak is the most readily available source of anti-EVD antibodies. Until the advent of effective antivirals or monoclonal antibodies, CP merits further evaluation.
U2 - 10.1093/cid/civ680
DO - 10.1093/cid/civ680
M3 - A1: Web of Science-article
C2 - 26261205
SN - 1058-4838
VL - 62
SP - 69
EP - 74
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 1
ER -